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Abstract.
The synthesis and characterization of four di- and tri-n-butyltin cysteaminates and_
N,N-dimethylcysteaminates and three protonated / quaternized derivatives are reported. They
all exhibit moderate or high in vitro cytotoxic activity. Six of seven compounds presented in
this work are more active than cisplatin, etoposide and 5-fluorouracil, but less active than
methotrexate and doxorubiein.
Introduction.
Several organotin cysteaminates (aminoethylthiolates) have been studied 1-4 as
compounds with potentially high biological activity, but little is known about their cytotoxic
effect. The present paper reports the synthesis and characterization of di- and tri-n-butyltin
cysteaminates and their N,N-dimethyl analogues and their in vitro cytotoxicity.
It is shown that a correct evaluation of the biological activity of organotin compounds remains
r 5 often hampered by their low wate solubility. Therefore, we focused on the synthesis of
derivatives with potentially higher water solubility by introducing ionic groups into the
molecule by protonation or quatemization of a nitrogen atom.
Results and discussion.
3 2 4
(n-Bu)n Sn [SCH2-CH2-NHm(CH3)2-m]4-n
n=3, m=2 (1)
n=3, m=O (2)
n=2, m=2 (3)
n=2, m=O (4)
3 2 4
(n-Bu)3 Sn S-CH2-CH2-NHm(CH3)3.m X
n-Bu CH3-CH2-CH2-CH2
m=3, x=cn3so3 (5)
m 1, X=CH3SO3 (6)
m 0, X I (7)
Tri-n-butyltin cysteaminate (1), tri-n-butyltin N,N-dimethylcysteaminate (2), di-n-
butyltin bis(cysteaminate) (3) and di-n-butyltin bis(N,N-dimethylcysteaminate) (4) were
prepared by the reaction of the sodium cysteaminate (prepared in situ by the reaction of
sodium methylate with the hydrochloride of eysteamine) with the suitable di-or tri-n-butyltin
chloride in chloroform following reference
The methanesulphonates 5 and 6 were respectively synthesized by the reactions of the
unprotonated analogs 1 and 2 with an equimolar amount of methane sulphonic acid in
chloroform. After purification on a short column of alumina and evaporation of the solvent,
colourless viscous oils were obtained. The quaternized methyl derivative of 2, the methiodide
(7), was prepared by its reaction with methyl iodide in benzene and purified by recrystalization
from chloroform.
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Table 1. Melting points and yields for..c0mP0unds 1 7.
comp. ()rmula,2
1
2
3
4
5
6
7
(C4H9)3SnSCHzCH2NH2
(C4H9)3SnSCHzCH2N(CH3)2
(C4H9)2Sn(SCH2CH2NH2)2
(C4Hg)zSn(SCH2CHzN(CH3)2)2
(C4H9)3SnSCH2CH2NH3 CH3SO3
(C4H9)3SnSCH2CH2NH(CH3)2 CH3SO3
(C4H9).SnSCH.CH.N(CH3)31
’o’ m.p., ..b.p.., .C yield,.%
120-123/40 Pa 86
129-131/35 Pa 77
167-169/35 Pa 85
172-174/40 Pa 90
oil 92
oil 94
118-120 74
The elemental analyses (C, H, N, Sn) agree satisfactorily with the proposed formul
Compounds 1- 4, and 7, are poorly soluble in aqueous solutions (< mg/mL).
Compounds 5 and 6 exhibit higher water solubilities (ca. 2 mg/mL). Compounds 1 7 are
soluble in a therapeutic solution (0,103 M solution ofNaCl in water/DMSO 1/9). A white
turbidity appears in these solutions only after several hours due to slow hydrolysis.
Compounds 1 7 were characterized by multinuclear NMR spectroscopy. The NMR
parameters are given in Table 2.
Table 2. Resonances of 13C, SN and ll9Sn NMR spectra of the compounds 1-7 in CDCI3
1’ 2 3 4 5 6’ 7
77.6 77.5 -28.9 38.’ 86.3 ’89.5 93.2
12.3 12.75 22.38 18.78 13.45 13.45 13.60
(332) (331) (495) (438) (322) (350) (339)
27.93 27.97 28.27 27.51 28.30 28.34 28.47
(21.3) (21.1 ) (28.4) (26.4) (21.4) (21.3) (22.0)
26.32 26.38 26.42 25.90 26.85 26.81 26.91
(59.6) (59.8) (87.1) (83.8) (62.7) (61.4) 62.2)
12.89 12.95 13.35 12.82 13.45 13.58 14.00
(-) (-) (-) (-) (-) (-; (-)
30.31 23.59 30.04 23.84 23.92 20.94 19.70
45.02 63.12 44.44 61.84 43.08 60.94 69.49
44.71 44.46 43.42 54.18
39.15 39.16
-360.4 -354.0 -355.3 -354.4 -349.4 -344.2 -325.8
1.1 1.5 6.2 1.5 12.7 11.7 30.1
(ca 20% sol. v/v)
compound
6’ ’S’n), "ppm
6(3c)a, ppm x
n n 9 13 a’values of J( J Sn, ,C) c0uplihg constants in Hz’for Carbon ato]ns in parentlee’s
difference btween (N) for the organo.i compound and free cysteamine, 6(N)
361.5 ppm; N,N-dimethylcysteamine, 5(N) -355.9 ppm)
not observed
13 n 119 13 C resonances were assigned on the basis of the values of J( Sn, C) coupling constants and
13 standard C- APT techniques utilization in agreement with ref..
119 The values of Sn chemical shifts are found in the interval characteristic for four-
coordinated tin6,7. The values of the coupling constants j(1 lqSn,13C) agree with the structure
proposed. Compound 3 is characterized by a somewhat larger upfield shift, close to the upper
limit of the above mentioned interval, together with a high value of 1j(l lqSn,13C) (495 Hz).
67 The C-Sn-C angle, est’mated, from this value of coupling constant is 124. According to ref.,
this behaviour can be due to intermolecular association increasing the coordinatitn number of
tin in concentrated solutions, as suggested by the concentration dependence of tS( Sn) and
cryoscopic measurements in benzene.
The values of the 6(SN)chemical shifts of compounds 1, 2 and 4 only slightly differ
from the (15N) values of the free cysteamine. The significantly larger i(15N) chemical shift of
compound 3 is however much lower than those of compounds 5, 6 and 7 containing a
tetracoordinated nitrogen atom. It can be stated that the Sn -
N interaction in compounds 1
4 is negligible or only very weak in chlorofom solutions. This conclusion is not in
contradiction with the proved Sn --
N interaction found in the solid state8.
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Antitumour activity.
The results of the in vitro antitumour tests of compounds 1 7 are given in Table 3 as
the inhibition doses IDs0 observed against a panel of seven human tumour cell lines, MCF-7 and
EVSA-T, two breast cancers, WiDr, a colon cancer, IGROV, an ovarian cancer, M19 MEL, a
melanoma, A248, a renal cancer, and H226, a non-small cell lung cancer. The antitumour tests
results are compared with those obtained for clinically used reference compounds9 like
cisplatin, doxorubicin, etoposide, 5-fluorouracil and methotrexate.
Table 3. Inhibition doses IDs0 of compounds 1- 7 and of five reference compounds.
comp.
1
2
3
4
5
6
7
cisplatin
doxorubicin
etoposide
5-fluorouracil
methotrexate
MF-7 EVSA-T WiDr IGROV M19MEL A498 H226
41 33 39 44 67 85 39
41 35 39 46 78 88 39
51 45 211 68 72 118 70
78 65 331 110 112 129 108
30 <3 19 29 31 42 36
90 57 40 83 77 133 111
385 367 339 411 327 758 576
699 422 967 169 558 2 253 3 369
10 8 11 60 16 90 199
2 594 317 150 580 505 314 3 934
750 475 225 297 442 143 340
18 5 <3 7 23 37 2 287
It is evident from Table 3 that all studied compounds exhibit excellent cytostatic
activities, except compound 7 showing only moderate activity. Compounds 1 6 are more
active than cisplatin and, in most cases, than etoposide and 5-fluorouracil. Their activity is
lower than that of doxorubicin and methotrexate in most cases for the studied cancer cell lines.
The very limited set of acquired activity values show that the activity of tri-n-butyltin
compounds are higher than those of di-n-butyl analogues (1>3, 2>4) for all cell lines, especially
against WiDr. The N,N-dimethyl derivatives exhibit an activity comparable to or somewhat
higher than that of unmethylated compounds. Compound 8, with a quaternized nitrogen,
exhibits the lowest cytotoxic activities, approximatively 9 times lower than compound 2. It
might be underlined that the ionic more water-soluble compounds 5 and 6 are not more active
than the uncharged analogs 1-4, whereas the hydrophilic organotin polyoxacarboxylates
51 exhibit much higher in vitro activities than other organotin carxylates Compounds 5 and 6
(with a protonated nitrogen) exhibit activities comparable or even considerably higher
(compound 5)against EVSA-T than the corresponding unprotonated compounds. Compound 7
(with a quaternized nitrogen) exhibits the lowest cytostatic activities, approximately 9 times
lower than compound 2. It should however be mentioned that another ionic organotin
compound, bis(dicyclohexyl)ammonium bis(2,6-pyridinecarboxyla,to)di-n-butylstannate, where
the organotin moiety is this time anionic, is also as active as the uncharged analogl.
Instrumentation.
All NMR spectra were recorded on a Bruker AMX 360 instrument using a 5 mm
multinuclear tuneable probe. The residual CHCI3 resonance at 7.24 ppm was used as reference
for the H soectra and the central 13CDCI3 resonance at 77.0 ppm, for the 13C spectra. The
119 119 15 Sn chemical shifts were refered to the external tetramethyltin [6( Sn) 0.0]. The N
NMR spectra were measur;l using the INEPT technique or in inverse-gated mode. (reference:
external nitromethane, [5(’N) 0.0]).
The protocol followed for the in vitro antitumour screenings has been already
reported10.
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